Selecting the most effective molecules for drug delivery is often a trial-and-error process, but Cornell engineers are providing some precision thanks to a technique that reveals the performance of those molecules inside living cells.
New study uses machine learning on ultrasound images of thyroid nodules to predict risk of malignancy
The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of killer T cells, the foot soldiers of the immune system.
New guidance from exercise oncology experts recommend systematic use of an “exercise prescription” by health care workers and fitness professionals in designing and delivering exercise programs that aim to lower the risk of developing certain cancers and best meet the needs, preferences and abilities of people with cancer. 17 organizations reviewed the latest scientific evidence and offer recommendations about the benefits of exercise for prevention, treatment, recovery and improved survival.
Patients pay less out-of-pocket for metastatic breast cancer (MBC) treatment that aligns with recommendations from NCCN Guidelines, according to a new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
A randomized clinical trial led at Children's Hospital Los Angeles by Leo Mascarenhas, MD, MS, showed first positive results in rhabdomyosarcoma since 1974.
Sixteen years ago, a research group at Mayo Medical School published results showing that a protein called TRAIL can kill cells that cause liver fibrosis but no one seemed to follow up on these findings. Now, researchers at Johns Hopkins Medicine have improved on this protein and shown that it selectively kills cells that cause the hardening of skin associated with scleroderma, effectively reversing the condition in mice genetically engineered to mimic the disease. A report on these results was published earlier this year in Nature Communications.
A premier educational event sponsored by the Johns Hopkins Kelly Gynecologic Oncology Service and the Division of Gynecologic Oncology at Sibley Memorial Hospital, this one-day conference gathers more than 25 experts to provide cancer survivors and their caregivers
Jada Lucas, a 22-year-old bone marrow recipient from Birmingham, met the bone marrow donor who helped save her life — Jerome Lewis of Philadelphia, Penn. — at donor registry event at Children's of Alabama.
As a disposable version of the instrument used in one of the most common medical procedures in the United States inches closer to widespread availability, a team of Johns Hopkins data researchers is studying the economic and safety implications associated with the devices used to perform colonoscopies.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
In an extensive “data mining” analysis of British medical records, researchers at the Johns Hopkins Kimmel Cancer Center conclude that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer—but not rectal cancer—a decade later. The findings, reported in the August 20 issue of the journal Gut, highlight the need for judicious use of this broad category of drugs, which are frequently improperly or overprescribed, the report authors say.
With a $2.14 million grant from the National Cancer Institute (NCI), researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University will measure whether an approach that uses simulation or experiential learning can affectively teach family caregivers not only the skills to take better care of their patient, but better care of their own emotional and physical health amid such incredible stress.
A next-generation clinical trial program and the first-ever adaptive platform trial for brain cancer, GBM AGILE is a move away from the traditional, one-size-fits-all approach to clinical trials – a major step forward for Precision Medicine.
Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they’ve completed locally ablative therapy almost tripled the median progression-free survival compared to the historical average.
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.
In experiments in mice, Johns Hopkins researchers say they have developed a technique that facilitates the precise placement of cancer drugs at their intended targets in the brain. This approach pairs a technique that guides a catheter through the brain’s arteries with positron emission technology (PET) scans to precisely place cancer drugs at their intended targets in the brain. If future studies show this image-guided drug delivery method is safe and effective in humans, the researchers say it could improve outcomes for historically difficult-to-treat and often lethal brain cancers, such as glioblastoma.
Rutgers Cancer Institute experts share more about the importance of preventative screenings for colorectal and lung cancers.
Delays in diagnosis and use of under-resourced health centers account for most racial and ethnic disparities when it comes to a timely breast cancer diagnosis, according to a new study.
A change in the genome of Caucasians could explain much-higher rates of the most common type of esophageal cancer in this population, a new study finds. It suggests a possible target for prevention strategies, which preliminary work suggests could involve flavonoids derived from cranberries.
Researchers have identified an independent prognostic factor, cancer/testis antigen 45, that is associated with extended disease-free survival for women with advanced ovarian cancer. Patients with high levels of CT45 in their tumors lived more than seven times as long as patients who lacked sufficient CT45.
Research from the St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project has revealed new vulnerabilities and leads for treatment of rhabdomyosarcoma
Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Adult survivors of childhood cancer should be screened for financial problems that might cause them to delay or skip medical care or to suffer psychological distress. The recommendation from St. Jude Children’s Research Hospital researchers followed an analysis that found 65 percent of survivors reported financial challenges related to their childhood cancer diagnoses. More than half of survivors (51.1 percent) indicated they worried about paying for care, and 33 percent said finances kept them from seeking medical care.
Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 (DYRK2) at the atomic level. This previously unreported biochemical interaction of curcumin leads to inhibition of DYRK2 that impairs cell proliferation and reduces cancer burden.
Up to 50% of women skip potentially life-saving mammograms often because they can cause extreme discomfort. Now researchers have developed a painless, light-based, non-radioactive, 15-second procedure that could revolutionize breast cancer screening and save lives.
A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations.
While a wide majority of oncologists do not feel informed enough about medical marijuana’s utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend it to their patients, say researchers who surveyed a population-based sample of medical oncologists.
Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.
Research by Rutgers Cancer Institute of New Jersey investigators explores the use of a diabetes drug and its impact on pancreatic cancer and finds that targeting a certain signaling pathway with this agent may be a novel strategy for the prevention and treatment of metastatic pancreatic cancer.
Researchers at UC Davis have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer Registry and the Patient Discharge Dataset, the team determined that the risk was reduced by 53 percent. These findings were reported in February in the journal Cancer.
In JCI Insight, researchers reported the results of a phase I, multi-institution clinical trial for an investigational treatment for melanoma and other cancers with mutations in the BRAF or RAS genes.
UNC and NC State scientists created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results in animal models suggest this approach could one day ramp up therapeutic benefits for cancer patients.
Combining ultrasound imaging with a blood test for high alpha fetoprotein (AFP) levels improves detection of early-stage liver cancer by as much as 40 percent, researchers at UT Southwestern’s Simmons Cancer Center found.
Bursting oxygen-filled microbubbles in breast cancer makes tumors three times more sensitive to radiation therapy in preliminary tests with animal models of the disease
A new anti-cancer strategy wields light as a precision weapon. Unlike traditional light therapy — which is limited to the skin and areas accessible with an endoscope — this technique can target and attack cancer cells that have spread deep inside the body, according to researchers at Washington University School of Medicine in St. Louis.
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.
A study led by St. Jude Children’s Research Hospital found germline variations in a key tumor suppressor gene that may prompt changes in treatment and follow-up care for certain high-risk leukemia patients
Researchers at the University of Michigan Comprehensive Cancer Center uncovered a novel gene they named THOR. It's a long non-coding RNA that plays a role in cancer development. Knocking it out can halt the growth of tumors.
St. Jude Children’s Research Hospital scientists report that combining the anti-malaria drug DHA with an emerging class of targeted agents may improve treatment of a high-risk acute lymphoblastic leukemia subtype
Researchers from Harvard Medical School and the Institute of Systems Biology have discovered that the remains of tumor cells killed by chemotherapy or other cancer treatments can actually stimulate tumor growth by inducing an inflammatory reaction. The study, which will be published November 30 in The Journal of Experimental Medicine, also reveals that a family of molecules called resolvins can suppress this unwanted inflammatory response, suggesting new ways to enhance the effectiveness of existing cancer therapies.
Too much, too little, just right. It might seem like a line from “Goldilocks and the Three Bears,” but actually describes an important finding that will enhance computer-aided diagnosis (CADx) of melanoma.
The CORE Prize for Oncology 2017 was awarded to Professor Antonio Giordano for his groundbreaking discoveries in the field of the cell cycle, which have established an understanding of the fundamental mechanisms at the basis of cancer and the development of a new class of anticancer therapeutics.
Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells.
In an analysis of the impact of parity laws published in JAMA Oncology, UNC Lineberger Comprehensive Cancer Center researchers and collaborators from Harvard Medical School report modest improvements in costs for many patients. However, patients who were already paying the most for their medications, saw their monthly costs go up.
UVA is testing the power of focused ultrasound and immunotherapy to enable the body to identify and destroy metastatic breast cancer cells.
A new study from the Keck School of Medicine of USC has found that IUD use is associated with a dramatic decrease in the incidence of cervical cancer.
A study led by UNC Lineberger Comprehensive Cancer Center researchers found that preference for preserving sexual function was not strongly reflected in the treatment choices of men with low-risk prostate cancer.
Some scientists have suspected that the most common form of ovarian cancer may originate in the fallopian tubes, the thin fibrous tunnels that connect the ovaries to the uterus. Now, results of a study of nine women suggest that the genomic roots of many ovarian tumors may indeed arise in the fallopian tubes, potentially providing insights into the origin of ovarian cancer and suggesting new ways for prevention and intervention of this disease.
In a study in today’s issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate. Their earlier research—which first implicated nerves in fueling prostate cancer—has prompted Montefiore-Einstein to conduct a pilot study testing whether beta blockers (commonly used for treating hypertension) can kill cancer cells in tumors of men diagnosed with prostate cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right